DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

Chao Zhang, Hong Lei Zhang, Meng Nan Han, Xue Li Yang, Chao Hong Pei, Zhi Dong Xu, Jie Du, Wei Li, Shengxi Chen

Research output: Contribution to journalArticle

1 Scopus citations


Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

Original languageEnglish (US)
Pages (from-to)1982-1989
Number of pages8
JournalRSC Advances
Issue number4
StatePublished - Jan 1 2019


ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)

Cite this

Zhang, C., Zhang, H. L., Han, M. N., Yang, X. L., Pei, C. H., Xu, Z. D., Du, J., Li, W., & Chen, S. (2019). DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy. RSC Advances, 9(4), 1982-1989. https://doi.org/10.1039/C8RA08735K